# Cilengitide in Treating Patients With Prostate Cancer

> **NCT00121238** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 16 (actual)

## Conditions studied

- Recurrent Prostate Cancer
- Stage I Prostate Cancer
- Stage IIA Prostate Cancer
- Stage IIB Prostate Cancer
- Stage III Prostate Cancer

## Interventions

- **DRUG:** cilengitide

## Key facts

- **NCT ID:** NCT00121238
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2010-11
- **Final completion:** 2015-11
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2016-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121238, "Cilengitide in Treating Patients With Prostate Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00121238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*